ClinicalTrials.gg

Program

CDK2 Inhibitor INCB123667

Its studies are mostly in Ovarian Neoplasms · Kidney Failure, Chronic · Hepatic Insufficiency, led by Incyte.

Furthest: phase 3, since Oct 6, 20257 company-led studies, 5 open or runningNext primary completion: Jan 4, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte75 open or runningphase 3since Oct 6, 2025Mar 27, 2025Jan 4, 2027phase 1 · NCT07559396

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT06909162 · 51 enrolled · United States
  2. Jun 9, 2025Phase 2 study in Ovarian NeoplasmsNCT07023627 · 160 planned · United States, Australia, Belgium and more
  3. Oct 6, 2025Phase 3 study in Ovarian NeoplasmsNCT07214779 · 466 planned · United States, Australia, Belgium and more
  4. Oct 16, 2025Phase 1 study in Healthy ParticipantsNCT07218744 · 9 enrolled · United States
  5. Apr 24, 20262 phase 1 studiesNCT07559474, NCT07559396
  6. Aug 26, 2026Phase 3 study in Ovarian NeoplasmsNCT07797283 · 590 planned

Ahead

  1. Jan 4, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07559396
  2. Apr 13, 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07559474
  3. Apr 27, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT07023627
  4. Nov 15, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07214779

TargetBeta

CDK2 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule

Other programs on CDK2

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
tegtociclibPfizerphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CDK2 Inhibitor AVZO-021ruleavenzo-therapeutics-incphase 22
CDK2 Inhibitor ECI830Novartisphase 21
CDK2 Degrader BG-75098ruleBeOne Medicinesphase 11
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
ZE94-0605ruleeilean-therapeuticsphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07797283Ovarian Neoplasms3Not yet recruitingMay 1, 2032590
NCT07559474Hepatic Insufficiency · United States1RecruitingApr 13, 202716
NCT07559396Renal Insufficiency · United States1RecruitingJan 4, 202716
NCT07218744Healthy Participants · United States1CompletedDec 10, 20259
NCT07214779Ovarian Neoplasms · United States, Australia, Belgium and more3RecruitingNov 15, 2028466
NCT07023627Ovarian Neoplasms · United States, Australia, Belgium and more2RecruitingApr 27, 2027160
NCT06909162Healthy Participants · United States1CompletedMay 17, 202651

How it is read

Names in the registry

  • “INCB123667”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.